The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era

K Floyd, P Glaziou, A Zumla… - The Lancet Respiratory …, 2018 - thelancet.com
Tuberculosis is the number one cause of death from infectious disease globally and drug-
resistant forms of the disease are a major risk to global health security. On the occasion of …

Cyclobutanes in small‐molecule drug candidates

MR van der Kolk, MACH Janssen, FPJT Rutjes… - …, 2022 - Wiley Online Library
Cyclobutanes are increasingly used in medicinal chemistry in the search for relevant
biological properties. Important characteristics of the cyclobutane ring include its unique …

The role of vaccines in preventing bacterial antimicrobial resistance

KU Jansen, C Knirsch, AS Anderson - Nature medicine, 2018 - nature.com
Antimicrobial resistance (AMR) and the associated morbidity and mortality due to bacterial
pathogens have been increasing globally to alarming levels. The World Health Organization …

Advances in the development of new tuberculosis drugs and treatment regimens

A Zumla, P Nahid, ST Cole - Nature reviews Drug discovery, 2013 - nature.com
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data

L Wang, H Zhang, Y Ruan, DP Chin, Y Xia, S Cheng… - The Lancet, 2014 - thelancet.com
Background China scaled up a tuberculosis control programme (based on the directly
observed treatment, short-course [DOTS] strategy) to cover half the population during the …

Tuberculous meningitis: more questions, still too few answers

GE Thwaites, R van Toorn, J Schoeman - The Lancet Neurology, 2013 - thelancet.com
Tuberculous meningitis is especially common in young children and people with untreated
HIV infection, and it kills or disables roughly half of everyone affected. Childhood disease …

Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled …

G Theron, L Zijenah, D Chanda, P Clowes, A Rachow… - The Lancet, 2014 - thelancet.com
Summary Background The Xpert MTB/RIF test for tuberculosis is being rolled out in many
countries, but evidence is lacking regarding its implementation outside laboratories, ability to …

Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development

L Imamovic, MOA Sommer - Science translational medicine, 2013 - science.org
New drug deployment strategies are imperative to address the problem of drug resistance,
which is limiting the management of infectious diseases and cancers. We evolved resistance …

Therapeutic evolution of benzimidazole derivatives in the last quinquennial period

W Akhtar, MF Khan, G Verma… - European journal of …, 2017 - Elsevier
Benzimidazole, a fused heterocycle bearing benzene and imidazole has gained
considerable attention in the field of contemporary medicinal chemistry. The moiety is of …

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

SD Lawn, P Mwaba, M Bates, A Piatek… - The Lancet infectious …, 2013 - thelancet.com
Rapid progress has been made in the development of new diagnostic assays for
tuberculosis in recent years. New technologies have been developed and assessed, and …